Securities and Exchange Board of India (Sebi) has imposed a penalty of Rs 40 lakh on Ankur Drugs and Pharma for its failure to make quarterly disclosures to the NSE about the shares pledged by promoters as was required under the takeover norms.
As per the takeover norms, if the aggregate number of pledged shares of a promoter or every person forming part of promoter group taken together with shares already pledged during that quarter by such promoter or persons exceeds twenty five thousand or 1% of total shareholding of the company, then the company is necessary to disclose such details to the concerned stock exchanges within 7 working days.
The company has failed to make quarterly disclosures to NSE in respect of the aggregate number of shares pledged/ encumbered by the promoters during the quarters ending March 2010 to December 2011, which was in excess of 25,000 shares or 1% of the total share capital of the notice.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: